Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

Who Took Part

According to the abstract, 15 participants were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

This analysis focuses on the first 11 of 15 weeks where participants used their routine pump therapy with continuous glucose monitoring (CGM), where remote follow-ups were performed on days 7, 21, 32, 56, 63, and 77 (± 4 days).

Changes in insulin requirements, carbohydrate input, and pump parameters over time compared to baseline were assessed, as well as the frequency of parameter adjustments.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Semaglutide, giving a reference point.

Each person switched between Semaglutide and the comparison at some point, usually with a gap in between.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 1, Insulin Infusion Systems, Glucagon-Like Peptides, Hypoglycemic Agents, Insulin, Blood Glucose and Blood Glucose Self-Monitoring.

Author keywords: GLP1 analogues, automated insulin delivery, continuous glucose monitoring, insulin pump therapy, semaglutide and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 15 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, all human trials.